The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Important prognostic factors to evaluate in CLL patients in the era of small molecules
In this video, William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into important prognostic and diagnostic factors to evaluate in patients with chronic lymphocytic leukemia (CLL), including the presence of del(17p), TP53 mutation status, and IgHV mutation status. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
